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Introduction
The tumor necrosis factor (TNF) ligand and TNF/nerve
growth factor (NGF) receptor families provide a unique
point of view of biological regulation. (For a list of alternative
names of receptors and ligands, see website [1]. See Fig. 1
for a schematic presentation of the known interactions
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Chapter summary
Signals emanating from receptors of the tumor necrosis factor/nerve growth factor (TNF/NGF) family
control practically all aspects of immune defense and, as such, constitute potential targets for therapeutic
intervention through rational drug design. Indeed, arrest of these signals by blocking ligand–receptor
interactions enables effective suppression of a variety of activities that are implicated in various
pathologies, such as T and B lymphocyte activation and growth, inflammation, fibroblast proliferation, and
cell death. To be therapeutically useful, however, inhibition of signaling should be restricted by
determinants of specificity, at least to the same degree observed when blocking activation of individual
receptors. In spite of their broad range of functions, receptors of the TNF/NGF family are known to
activate just a few signaling pathways. Of these, the most extensively studied are the activation of the
caspase protease cascade, which leads to cell death, and the activation of NF-κB (nuclear factor-κB)
transcription factors through protein phosphorylation cascades. Until recently, most studies of the two
pathways have solely focused on the core signaling complexes that are shared by the different receptors:
death-inducing complexes containing the cysteine proteases caspase-8 and caspase-10, bound to the
adapter protein MORT1/FADD (mediator of receptor-induced toxicity/Fas-associated DD protein), and
the NF-κB-activating complex, composed of the protein kinases IKK1 (IκB kinase 1) and IKK2 (IκB kinase
2) and the regulatory subunit NEMO (NF-κB essential modulator; the ‘IKK signalosome’). Knowledge has
begun to emerge of additional molecules and mechanisms that affect these basic signaling complexes
and impose specificity on their function.
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between them.) These receptors and ligands are
expressed in almost all cells and trigger a wide range of
different, in part contrasting, cellular activities [2–5]. They
help to regulate practically every aspect of immune
defense, as well as certain developmental processes. All
of these activities are mediated by a unique set of appar-
ently few signaling proteins, which are shared by the dif-
ferent receptors [6].
Understanding how such a heterogeneous group of func-
tions can be elicited by a limited number of signaling pro-
teins and, just as importantly, how the signaling system
‘decides’ which of its potential downstream pathways will
be activated in a given situation is not solely a matter of
academic interest. As demonstrated by the efficacy of
anti-TNF therapy in diseases such as rheumatoid arthritis
[7], understanding the mechanisms of action of the
TNF/NGF receptor family at the molecular level bears
immense therapeutic potential. Studies in our laboratory
have helped to elucidate two aspects of specificity in the
functioning of the signaling pathways: mechanisms that
determine whether cell death or a noncytocidal effect is
induced, and mechanisms that impose specificity of action
on the enzymes that activate the highly pleiotropic nuclear
factor-κB (NF-κB) transcription factors.
A cell death pathway that is independent of,
yet controlled by, gene activation
Several members of the TNF/NGF receptor family are
capable of inducing cell death. Those doing so most effec-
tively, collectively known as ‘death receptors,’ share an
intracellular motif, the so-called ‘death domain,’ through
which their cytotoxic activities are mediated. Much of our
current understanding of their mode of toxicity arises out of
studies of the earliest-known members of the TNF ligand
family, TNF itself and lymphotoxin-α. Almost from the first, it
was noted that the ability of these cytokines to kill cells is
independent of protein synthesis, but, rather, is strongly
potentiated by inhibitors of protein synthesis [8–10].
Once it became evident that this cytotoxicity is receptor
mediated [11], it followed that the cytocidal effect is
exerted by activation of death-inducing signaling proteins
that pre-exist in the living cell. It also followed that there
exist in cells protein-synthesis-dependent ‘antideath’ func-
tions. One could further deduce from these early studies of
TNF cytotoxicity that the protein-synthesis-dependent ‘anti-
death’ functions are in part activated by TNF itself [12].
Current knowledge of the molecular mechanisms of cell
death induction by the death receptors enables
Figure 1
Schematic drawing of the known interactions between members of the TNF ligand family and members of the TNF/NGF receptor families. Death
domains are indicated as black boxes (or gray boxes, in the cases of NGF-R and EDAR). EDAR, ectodysplasin-A receptor; NGF, nerve growth
factor; NGF-R, receptor for nerve growth factor; TNF, tumor necrosis factor.S191
delineation of a continuous pathway that begins with the
triggering of receptor signaling by ligands and ends with
certain specific morphological and functional manifesta-
tions of programmed cell death. Acting on the assumption
that the apoptotic mechanism activated by the death
receptors involves solely cellular components that have
pre-existed in the cell before death is triggered, attempts
to identify these components have centered on analyses
of the protein–protein interactions initiated by the stimu-
lated receptors.
Two-hybrid screens led firstly to the identification of three
adapter proteins, MORT1/FADD [13,14], TRADD [15],
and RIP [16], all of which contain death domains that bind
to the death domains in the receptors. Subsequent two-
hybrid screens and analysis of the composition of the sig-
naling complex associated with the death receptor Fas led
to the identification of caspase-8 (MACH/FLICE [MORT1-
associated CED3 homologue/FADD-like interleukin-1-con-
verting enzyme]), a cysteine protease that is recruited to
the receptor complex through its binding to MORT1/
FADD and, once activated there, initiates the cell death
process [17,18]. A close homologue of caspase-8,
caspase-10, is similarly recruited and also serves to initi-
ate the apoptotic process [19–21].
Once activated, caspase-8 and caspase-10 activate
other members of the caspase family, the so-called ‘exe-
cutioner caspases’ such as caspase-3 and caspase-7,
either by direct proteolytic processing of their precursors
or indirectly, by triggering the release of cytochrome c
from the mitochondria: cytochrome c activates caspase-
9, which in turn processes and activates caspase-3 and
caspase-7. The ‘executioner’ caspases cleave target pro-
teins that play critical roles in specific aspects of the
death pathway. Two such examples are the processing of
I-CAD/DFF-45 (inhibitor of caspase-activated deoxy-
ribonuclease/45-kDa subunit of DNA fragmentation factor)
that leads to DNA degradation [22] and the cleavage
products of gelsoline, which participate in the process of
membrane blebbing [23].
The straightforward nature of the aforementioned pathway
(Fig. 2) highlights the need to clarify its regulation. If all
that it takes for the death receptor to trigger cell death is
just a short series of molecular interactions leading from
receptor activation to the eventual death events, how is it
that these same receptors so often elicit effects that are
not at all cytotoxic, and may even stimulate cell growth?
Knowledge emerging from the many laboratories that have
addressed this question implies that the ‘decision’ taken
by the death receptors either to induce cell death or to
exert noncytocidal effects is actually a summing up of mul-
tiple ‘antideath’ mechanisms that act at various mechanis-
tic levels [24]. Some of the mechanisms that prevent the
induction of cell death do so by arresting the recruitment
of the death-signaling proteins, thus enabling the recep-
tors to trigger other signaling molecules specifically
involved in noncytocidal functions.
Quite interestingly, however, protective mechanisms that
act by harnessing the same molecules that are dedicated
to the induction of cell death to noncytocidal functions
also seem to exist. Studies of the impact of targeted dis-
ruption of the genes encoding caspase-8 and its adapter
protein, MORT1/FADD, revealed that apart from signaling
for cell death, these same proteins also participate in the
processes triggering development of the heart muscle in
mammalian embryos and, at least in the case of
MORT1/FADD, triggering lymphocytic growth as well
[25–27].
Knowledge of the mechanisms that direct these death
molecules to noncytocidal functions is just beginning to
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Figure 2
Schematic drawing of the caspase pathway leading to cell death
induction by members of the TNF receptor family. DD, death domain;
DED, death-effector domain; TNF, tumor necrosis factor. For other
abbreviations, see Glossary of terms.S192
emerge. One of the proteins shown to participate in this
regulation is the enzymatically inactive caspase homo-
logue cFLIP. Several studies indicate that this protein is
recruited to the death receptors through MORT1/FADD,
where it not only blocks the activation of caspases, but
also, perhaps in conjunction with caspase-8, recruits addi-
tional signaling proteins (e.g. [28]).
Very recently, a caspase-8-binding protein called CARY
(caspase-8 binding protein with RNA-binding motifs) that
also seems to contribute to this regulation was discovered
in our laboratory. We propose that this protein acts at a
postreceptor level to regulate the activation of caspase-8
in the cytosol. Because CARY itself is cleaved by
caspase-8, its impact on the apoptotic process is tran-
sient. Modulations of the level of CARY in the cytoplasm,
either by its release from the nucleus, where large
amounts of this protein are stored, or by phosphorylation
of its caspase-8-mediated cleavage site, probably con-
tribute to variations in the levels of active caspase mole-
cules in the cell, which may well be a critical factor in
determining whether or not the effects of caspase activity
result in cell death (Fig. 3) (Goncharov MT et al., manu-
script in preparation).
As mentioned above, it was evident from the earliest
studies of cell death induction by TNF that while the death
mechanism itself is independent of protein synthesis, the
vulnerability of cells to TNF cytotoxicity is regulated by
protein synthesis mechanisms and that the activities of at
least some of the proteins protecting cells from TNF cyto-
toxicity are induced by TNF itself. A major advance
towards understanding this regulatory process was the
identification of the NF-κB transcription factor family as
involved in the induction of cellular self-resistance to TNF
cytotoxicity. The NF-κB transcription factors are known to
be activated by almost all of the members of the TNF/NGF
receptor family. Suppressing the activity of these tran-
scription factors greatly sensitizes cells to the cytotoxic
effects of TNF and various other agents (reviewed in [29]).
Indeed, the genes for several of the proteins known to play
a role in regulating the cytotoxic effects of members of the
TNF/NGF family are regulated by NF-κB (e.g. [30]).
Specificity in the activation of NF-κ κB
An additional major challenge to our understanding of the
nature of specificity in the signaling mechanisms of the
TNF/NGF family of receptors is posed by the way they
activate NF-κB. The core mechanism that activates NF-κB
was recently elucidated and was found to consist of a
macromolecular complex known as the IKK signalosome
[31]. This complex is composed of two protein kinases,
IKK1 and IKK2. Both kinases phosphorylate IκB (inhibitor
of κB), an NF-κB inhibitory molecule, at specific sites, thus
targeting it for ubiquitinilation and consequent proteaso-
mal degradation.
Almost all of the receptors of the TNF/NGF family are able
to activate NF-κB and involve this activation in a significant
part of their gene regulatory effects, influencing a broad
spectrum of cellular functions,  only some of which
concern cell death. Some of the NF-κB-regulated func-
tions contribute to innate immunity and others to adaptive
immunity; still others affect certain aspects of embryonic
development. In every case, however, NF-κB activation by
the receptors was found to be mediated by the same
basic NF-κB-activating mechanism, the IKK signalosome.
Knowledge of the ways in which specificity is imposed on
this core mechanism is only now beginning to emerge.
Studies carried out mainly in the laboratory of David
Goeddel have demonstrated involvement of two adapter
proteins, TRAF2 and RIP, in the activation of NF-κB by
TNF. TRAF2 is a member of a family of adapter proteins
that shares among its members a C-terminal protein-
binding motif, the TRAF domain [32]. Other members of
the TRAF family are also known to participate in NF-κB
Arthritis Research    Vol 4 Suppl 3 Wallach et al.
Figure 3
A hypothetical model describing the proposed role of CARY (caspase-
8 binding protein with RNA-binding motifs) in controlling postreceptor
cleavage of pro-caspase-8. For abbreviations, see Glossary of terms.S193
activation by members of the TNF/NGF receptor family, as
well as by some other receptors [33]. RIP is a death-
domain-containing adapter protein that is recruited to the
p55 TNF receptor by the binding of RIP to TRADD,
another death-domain-containing protein, directly associ-
ated with this receptor [34,35].
Our own attempts to contribute to the understanding of
specificity in NF-κB activation have focused on exploring
the identity of the signaling proteins acting downstream of
these adapter proteins. By means of two-hybrid screens,
we succeeded in identifying several novel proteins that
bind to TRAF2 and, when overexpressed, modulate NF-κB
activation, suggesting that they participate in the activation
of NF-κB or in its regulation. One of the novel TRAF2-
binding proteins, a protein kinase that we called NIK
(NF-κB-inducing kinase) causes dramatic activation of
NF-κB when overexpressed. On the other hand, over-
expression of kinase-deficient mutants of this enzyme was
found to block the activation of NF-κB by a variety of dif-
ferent inducers [36]. This indiscriminate inhibition implies
that NIK is intimately associated with the core mechanism
of NF-κB activation. Indeed, subsequent studies revealed
that NIK binds directly to IKK1 and phosphorylates it [37].
Although there are still large gaps in our understanding of
NIK function, the evidence that is accumulating indicates
that this kinase possesses the ability to activate NF-κB in
response to specific inducers and for specific purposes.
Even though both the p55 TNF receptor and the lympho-
toxin-β receptor involve TRAF2 in NF-κB activation, NIK is
apparently activated only by the latter [38,39]. Stimulation
of the IKK signalosome by TNF leads to the activation of
an NF-κB complex comprising the NF-κB subunits p65
(RelA) and p50, and of IκB, through phosphorylation of
IκB induced by IKK2 (and consequent degradation of
IκB). However, stimulation of the IKK signalosome by NIK
also leads to the formation of another NF-κB subspecies,
p52, through induced phosphorylation of a p52 precursor,
p100 (NF-κB2) by IKK1 (and consequent proteolytic pro-
cessing of p100) (Fig. 4) [40,41].
It is not yet known which additional inducers other than
lymphotoxin-β involve NIK in their effect on NF-κB.
However, the phenotypes of mice with a natural point
mutation in NIK (the aly strain) and of mice with targeted
disruption of the NIK gene indicate that NIK specifically
mediates the effects of NF-κB-inducing agents that serve
to regulate adaptive immunity [39,42].
Among the proteins found in our two-hybrid screens to bind
to the other NF-κB activating adapter protein, RIP, we
focused on one, which we have initially called RAP2 (the
second RIP-associated-protein found in our screens). Unlike
NIK, RAP-2 was found to be devoid of any enzymatic func-
tion. Nevertheless, it dramatically modulated NF-κB activa-
tion. At low expression levels, it somewhat potentiated the
activation of NF-κB by a variety of agents, while at higher
expression levels, it strongly inhibited such activation.
This same protein was independently identified in several
other laboratories, where it has been called NEMO, IKKγ,
IKKAP1, and FIP3 [43–46]. Studies coming out of these
laboratories revealed that NEMO also binds to the two
protein kinases comprising the IKK signalosome, and in
fact constitutes an integral part of this macromolecular
complex. The coincidental identification of NEMO through
its binding to RIP and to the IKKs suggested that this
protein may function as a molecular link between the IKK
signalosome and specific inducers.
Indeed, in further analysis we found that NEMO is
recruited to the TNF receptor complexes along with the
other signalosome components [47]. It was later deter-
mined that a RIP homologue, RIP2/RICK, also binds to
NEMO and recruits the signalosome to a RICK-activating
intracellular receptor molecule, Nod1 [48]. Certain viral
proteins have also been shown to regulate the signalo-
some function by binding to NEMO [46,49].
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Figure 4
A model depicting the nuclear-factor-κB-activating pathways
described in this essay. For abbreviations, see Glossary of terms.S194
A more recent development in the study of NEMO func-
tion was the interesting finding that the C-terminal region
of this protein, which is comprised of a zinc finger domain,
is specifically involved in NF-κB activation by only some of
the TNF receptor family members. In both mice and man,
mutations in this region result in developmental deficien-
cies concerning the morphogenesis of hair, sweat glands,
and teeth that strongly resemble the deficiencies
observed when EDAR, a member of the TNF/NGF recep-
tor family, or its ligand is mutated. Such mutations also
result in a hyper-IgM syndrome, similar to that observed
when the CD40 ligand is mutated. However, they seem to
have little effect on NF-κB activation by TNF or bacterial
lipopolysaccharide [50,51]. By means of two-hybrid
screens, we recently identified several proteins that
specifically bind to the C-terminal region in NEMO and
may participate in the differential response to NF-κB
inducers mediated through this region.
It is gradually becoming evident that the activation of
NF-κB is much more complex than was originally per-
ceived soon after the discovery of the two kinases com-
prising the IKK signalosome. It is now known that NF-κB
activation involves several different molecular events in
both the cytosol and the nucleus and is affected by multi-
ple regulators. Though our knowledge of these mecha-
nisms is still fragmentary, one important implication of our
current understanding is that, although the same core mol-
ecular complex, the IKK signalosome, participates in the
activation of NF-κB by a variety of different inducers, this
core complex displays sufficient complexity of interaction
to allow for specificity of regulation.
Concluding remarks
With some regret, we are watching the gradual replace-
ment of the simple and elegant initial models of signaling
mechanisms for cell death and NF-κB activation by
members of the TNF/NGF receptor family with models of
much greater complexity. This loss of elegance is surely
worthwhile, as the new, more complex models further our
understanding of the ways in which the simple set of sig-
naling molecules known to be activated by members of
the TNF/NGF receptor family can coordinate the broad
and heterogeneous range of activities controlled by these
receptors, without apparent self-contradiction. In essence,
we are gradually learning that this simple set of signaling
molecules constitutes only the framework within which a
much more complex set of molecules interacts, imposing
specificity on its action.
There is also an obvious applicative value to this emerging
complexity. Understanding the workings of biological regu-
lation at the molecular level provides us with potential
tools for medical manipulation of pathological deregula-
tion. It was the search for molecules that provide self-
resistance to TNF cytotoxicity that led researchers in our
laboratory and several others to the discovery, more than a
decade ago, of soluble TNF receptors in body fluids
[52–55]. This finding paved the way toward the current
use of engineered soluble TNF receptors to block TNF
function in diseases, such as rheumatoid arthritis, in which
TNF is a causative factor. One can just as well expect that
identification of regulatory molecules that impose speci-
ficity on the function of TNF/NGF receptors will lead to
more refined disease therapies designed to specifically
block the deleterious effects of these receptors, without
obliterating the beneficial ones.
Glossary of terms
CARY = caspase-8-binding protein with RNA-binding
motifs; DFF-45 = 45-kDa subunit of DNA fragmentation
factor; FADD = Fas-associated death-domain protein;
FIP3 = 14.7-K interacting protein 3; FLICE = FADD-like
inteleukin-1-converting enzyme; I-CAD = inhibitor of
caspase-activated deoxyribonuclease; IKK = IκB kinase;
IKKAP1 = IκB kinase-associated protein 1; MACH =
MORT1-associated CED3 homologue; MORT = mediator
of receptor-induced toxicity; NEMO = NF-κB essential
modulator; NIK = NF-κB-inducing kinase; RAP2 = RIP-
associated protein; RICK = RIP-like interacting CLARP
kinase; RIP = receptor-interacting protein; TRADD = TNF-
receptor-1-associated death-domain protein; TRAF =
TNF-receptor-associated factor.
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